DDInter1044 DDInter1376
Levamisole is an antihelminthic drug that was commonly used for the treatment of parasitic, viral, and bacterial infections. It was manufactured by _Janssen_ and first used in 1969 as an agent to treat worm infestations Levamisole was approved by the FDA in 1990 as an adjuvant treatment for colon cancer. Prior to this, levamisole was used as an antirheumatic therapy in the 1970s and 1980s for patients with rheumatoid arthritis. Because of its immunomodulatory effects, this drug has been studied in the treatment of various immune-mediated diseases, with some studies showing positive results. This drug has also been used in combination with other drugs for the treatment of various cancers. [A178117, A178123] Levamisole was withdrawn from the American market in 2000 due to its ability to cause serious adverse effects, including agranul
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Levamisole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alemtuzumab
Levamisole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ustekinumab
Levamisole {u} may lead to a major life threatening interaction when taken with {v} Samarium (153Sm) lexidronam
Levamisole {u} may lead to a major life threatening interaction when taken with {v} Infliximab
Levamisole may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab
Levamisole may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab
Levamisole may lead to a major life threatening interaction when taken with Samarium (153Sm) lexidronam
Levamisole may lead to a major life threatening interaction when taken with Infliximab